Kyverna Therapeutics, Inc. ( (KYTX) ) just unveiled an update.
Kyverna Therapeutics has appointed Warner Biddle as their new CEO and as a member of the Board, effective September 16, 2024. Biddle brings over 30 years of experience, including his previous role as Senior Vice President and Global Head of Commercial at Kite Pharma. He has a proven track record in product launches and commercial strategy, particularly in the cell therapy market. In addition, Christi Shaw, a veteran in the biopharmaceutical industry, has been appointed to Kyverna’s Board of Directors. The company also announced the resignation of Peter Maag, Ph.D., as CEO and director, and Brian Kotzin, M.D., from the Board. These leadership changes aim to strengthen Kyverna’s position in developing cell therapies for autoimmune diseases as they progress through clinical trials and approach market readiness.
For detailed information about KYTX stock, go to TipRanks’ Stock Analysis page.
